abrdn World Healthcare

National Advertising Review Board Refers Merck's Bravecto Dose Claim to FTC and FDA

Merck and Kailun Bio's Sac-TMT Succeeds in Phase III Endometrial Cancer Trial

Harvest Portfolios Group Inc. Increases Stake in Abbott by 5.4% Amid Strong Earnings

Medpal AI Launches New GLP-1 Sub-brand, Expects Novo Nordisk Oral Wegovy Approval in UK This Summer

Novo Nordisk to Unveil New Data on Semaglutide for Liver Disease Treatment

Novo Nordisk Initiates AMAZE 8 Clinical Trial to Test New Weight-Loss Drug Against Semaglutide

Novo Nordisk Advances New Cagrilintide Study, Boosting Competition in Obesity Treatment

Dr. Reddy's launches generic version of Novo Nordisk's Ozempic in Canada

Novo Nordisk plans to launch high-dose Wegovy in South Korea, competing with Eli Lilly in the obesity treatment market

French Regulators Fine Novo Nordisk and Lilly Over GLP-1 Campaigns

NVO Gains Competitive Insight from New Study Approvals

Novo Nordisk to Present New Analysis of Semaglutide ESSENCE Trial for MASH at 2026 EASL

Analysts Revise Novo Nordisk Price Targets Upwards Post-Q1 Earnings

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

Resona Asset Management Reduces Danaher Stake; Danaher Beats Earnings Expectations but Analysts Lower Price Target

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Novo Nordisk Updates Its AMAZE 12 Phase 3 Trial for Next Wave in Obesity Maintenance Drugs

Novo Nordisk will host a Capital Markets Day on September 21, 2026

Two Pharma Companies Now Own Nearly 100% of GLP-1 Citations Inside ChatGPT, Claude and Perplexity, New 5W Index Finds

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

MetaVia

Vida Global

Micware

BiomX

Tradr 2X Long XNDU Daily ETF

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

Ordinary dividend (cash)

Ex Date: 2026.05.21 (EST), Cash dividend 0.1167 USD

ARKG

The 2026 Milliman Medical Index reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase—the highest in over a decade. Key drivers include a 14.8% rise in pharmacy costs, influenced by GLP-1 drugs, and a 7.5% increase in outpatient facility costs. The report highlights the role of AI in optimizing billing processes, contributing to this significant cost growth.

- The Milliman Medical Index for 2026 reveals that healthcare costs for an average American family have reached $37,824, marking a 7.9% increase, the highest in over a decade.  
- Contributing factors include a 14.8% rise in pharmacy costs driven by GLP-1 drugs and high-cost specialty medications, alongside a 7.5% increase in outpatient facility costs.  
- Additionally, the introduction of artificial intelligence in billing processes is noted as a significant new factor in these rising costs.

MorningStar

Eli Lilly

Novo Nordisk AS

Ark Genomic Revolution ETF

SPDR S&P Health

iShares Global Healthcare

Defiance Daily Target 2X Long LLY ETF

Invesco Biotechnology & Genome ETF

Direxion Daily LLY Bull 2X Shares

Direxion Daily LLY Bear 1X Shares

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Defiance Daily Target 2X Long NVO ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR Pharmac

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VG Health

iShares US Pharma

Milliman Medical Index: Healthcare costs for an American family reach $37,824 in 2026

Novo Nordisk presented new data on semaglutide (Wegovy) at the EASL 2026 congress, highlighting its liver safety and efficacy in chronic liver disease, particularly for patients with Metabolic Dysfunction associated Steatohepatitis (MASH). The findings suggest potential broader applications for Wegovy beyond obesity and diabetes, especially for Japanese patients and menopausal women. Investors are keen to see how these results influence the company's narrative and market potential, while also considering associated risks.

Simplywall

Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors

The CDSCO has instructed states and UTs to monitor promotional activities for GLP-1 weight-loss drugs like semaglutide, following a ban on promotional activities for prescription-only therapies. The organization is enforcing compliance through audits and inspections, addressing illegal distribution and misuse. With the patent expiration of semaglutide, over 25 generic versions have emerged, prompting companies to launch multimedia campaigns focused on obesity awareness, as direct advertising is prohibited.

Business Standard

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

REGN

The FDA has granted breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a significant milestone for patients. Meanwhile, the agency faces instability with leadership departures, raising concerns about regulatory consistency. Additionally, Regeneron has entered a multibillion-dollar collaboration with Parabilis Medicines to develop new therapeutic candidates using AI-driven drug discovery.

Pharmexec

Regeneron Pharma

AstraZeneca

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

AstraZeneca received FDA approvals for Baxfendy, a hypertension treatment, and Enhertu for early HER2-positive breast cancer. Baxfendy targets uncontrolled hypertension, while Enhertu's approvals cover neoadjuvant and adjuvant settings. These milestones will result in $155 million payments to Daiichi Sankyo. AstraZeneca shares rose 1.56% to $184.42, despite a 9.1% decline over the past month.

Fidelity

AstraZeneca PLC

Mineralys Therapeutics

Daiichi Sankyo Company, Limited

Daiichi Sankyo

S&P 500

AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios

The FDA has approved Baxfendy (baxdrostat) for adults with hypertension inadequately controlled on other medications, marking the first aldosterone synthase inhibitor for this condition. The approval is based on the phase 3 BaxHTN trial, showing significant reductions in systolic blood pressure. This innovative treatment targets a root cause of uncontrolled hypertension, potentially transforming clinical practice. AstraZeneca's acquisition of Baxfendy ties it to a broader cardiorenal strategy, with future success dependent on market positioning and long-term outcomes.

<![CDATA[FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry]]>

DSNKY

4568

The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, approving it for neoadjuvant and adjuvant settings. The neoadjuvant approval is based on the DESTINY-Breast11 trial, showing a 67.3% pathologic complete response. The adjuvant approval, based on DESTINY-Breast05, demonstrated a 53% reduction in recurrence risk. These approvals enhance treatment options and have significant financial implications, including $155 million in milestone payments.

<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>

AstraZeneca has received U.S. approval for its hypertension drug, Baxfendy (formerly baxdrostat), which targets aldosterone to lower blood pressure. The company anticipates peak annual sales exceeding $5 billion. This approval enhances AstraZeneca's portfolio in cardiovascular and renal treatments, following the patent expiration of its diabetes drug, Farxiga. The FDA's decision was based on successful late-stage trials showing efficacy in patients with uncontrolled hypertension. AstraZeneca aims to launch 20 new medicines by 2030, targeting $80 billion in revenue.

CINCOR PHARMA INC

AstraZeneca Gets U.S. Approval for Hypertension Drug

HBM HOLDINGS-Bannounced preclinical data for LET003, a monoclonal antibody for obesity treatment developed using AI. The results indicate LET003 has superior pharmacokinetics compared to competitors and, when combined with semaglutide, enhances fat reduction while preserving lean mass. At lower doses, it matches the effects of higher-dose bimagrumab in promoting lean mass gain, suggesting its potential as a Best-in-Class obesity therapy.

AASTOCKS News

HBM HOLDINGS-B

HBM HOLDINGS-B  Discloses Preclinical Data of AI Candidate Drug for Obesity Treatment

The FDA has approved AstraZeneca and Daiichi Sankyo's ENHERTU for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on Phase III trial results. ENHERTU is now approved for adult patients with Stage II or III breast cancer and those with residual disease post-treatment. It is already approved in over 95 countries for metastatic breast cancer.

rttnews

AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings

abrdn World Healthcare(THW.US)